Replies to post #90914 on Biotech Values

[Biowatch]

Biovail BVF takes fourth quarter hit.

...Biovail also took an $11 million loss on the sale and leaseback of its corporate headquarters...

Amortization expense more than doubled to $34.3 million due to the Wellbutrin commercialization rights and costs from the acquisition of Prestwick Pharmaceuticals Inc.

http://finance.yahoo.com/news/Biovail-4Q-profit-falls-as-apf-3228478964.html?x=0&.v=1

Generic competition cuts into profits and reduces health care costs.

A balancing act...

But it beats the street's estimates:

an increase of 35% that primarily reflects higher revenues from Wellbutrin XL and the inclusion of revenues from tetrabenazine products and Aplenzin.

http://finance.yahoo.com/marketupdate/inplay#bvf